In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes
Open Access
- 1 November 2003
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (11) , 5209-5211
- https://doi.org/10.1128/jcm.41.11.5209-5211.2003
Abstract
We have compared the in vitro activity of the new antifungal drug eberconazole with those of three other topical antifungal agents, clotrimazole, ketoconazole, and miconazole, against 200 strains of dermatophytes. MICs were determined by a microdilution method with optimal conditions determined in a previous study (an inoculum of 10 4 CFU/ml, an incubation temperature of 28°C, an incubation period of 7 days, and a MIC endpoint of 100% inhibition of growth). In general, the four drugs tested showed low MICs. However, eberconazole was more active ( P < 0.05) than the other three drugs against the majority of the species tested. Eberconazole represents an advantageous alternative for dermatophytoses where a topical therapy is required.Keywords
This publication has 20 references indexed in Scilit:
- Collaborative Evaluation of Optimal Antifungal Susceptibility Testing Conditions for DermatophytesJournal of Clinical Microbiology, 2002
- Use of the Sensititre Colorimetric Microdilution Panel for Antifungal Susceptibility Testing of DermatophytesJournal of Clinical Microbiology, 2002
- Six Novel AntimycoticsAmerican Journal of Clinical Dermatology, 2002
- In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte StrainsAntimicrobial Agents and Chemotherapy, 2001
- Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double‐blind, multi‐centre, 8‐week clinical trialMycoses, 1999
- TerbinafineDrugs, 1999
- Onychomycosis – Treatment, Relapse and Re-InfectionDermatology, 1997
- Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose‐finding pilot studyMycoses, 1995
- IN VITRO SUSCEPTIBILITY OF DERMATOPHYTES TO ANTIFUNGAL DRUGS: A COMPARISON OF TWO METHODSInternational Journal of Dermatology, 1993
- Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder*Mycoses, 1992